Evidence map›Paper›PMID 34706776›Full record

ArticleJournal of medical case reports2021

Immunophenotypic challenges in diagnosis of CD79a negativity in a patient with B acute lymphoblastic leukemia harboring intrachromosomal amplification of chromosome 21: a case report.

A Berhili, M Bensalah, J ElMalki, A Elyagoubi, R Seddik

Open access · goldAbstract readCase Reports
In one paragraph

Article in Journal of medical case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

A BerhiliHematology Laboratory, Mohammed VI University Hospital, Oujda Universite, BP 4806, 60049, Oujda, Morocco. a.berhili@ump.ac.ma.ORCID https://orcid.org/0000-0002-0262-201X
M BensalahHematology Laboratory, Mohammed VI University Hospital, Oujda Universite, BP 4806, 60049, Oujda, Morocco.
J ElMalkiHematology Laboratory, Mohammed VI University Hospital, Oujda Universite, BP 4806, 60049, Oujda, Morocco.
A ElyagoubiHematology Laboratory, Mohammed VI University Hospital, Oujda Universite, BP 4806, 60049, Oujda, Morocco.
R SeddikHematology Laboratory, Mohammed VI University Hospital, Oujda Universite, BP 4806, 60049, Oujda, Morocco.
Mohamed I University · MA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBeing expressed in all stages of B-cell development and having a significant value on the European Group for the Immunological Characterization of Acute Leukemias scoring system, CD79a is considered as an excellent pan-marker for lineage assignment of B cells by flow cytometry. Therefore, any lack or decrease in CD79a expression makes the diagnosis of B acute lymphoblastic leukemia cases very challenging, especially in developing country laboratories where flow cytometry analyses are not always available and, when they are, they are limited in the number of markers used for lineage assignment. Since this case is potentially interesting, we report a B acute lymphoblastic leukemia case with a lack of expression CD79a associated with intrachromosomal amplification of chromosome 21 genetic abnormality. We further discuss the practical challenges in the diagnosis of this case. CASE PRESENTATION: We present the case of an 8-year-old Caucasian boy from eastern Morocco who was initially hospitalized for a hemorrhagic syndrome. Peripheral blood smear examination showed a significant number of blasts suggesting acute leukemia. Bone marrow was studied for morphology, cytochemistry, immunophenotyping, and cytogenetics. Flow cytometry analyses showed expression of CD19, CD22, CD10, CD34, and HLA-DR markers by leukemic blasts. The expression of CD79a, which was checked with two different monoclonal antibodies, confirms that this marker was severely decreased in this case. Cytogenetic study performed by fluorescence in situ hybridization revealed the presence of intrachromosomal amplification of chromosome 21, a cytogenetic abnormality that is specific for B acute lymphoblastic leukemia.

conclusionCD79a is one of the critical markers in the assignment of B acute lymphoblastic leukemia. In our case, we were lucky enough to be assisted by a few other markers of the B lineage that were positive in this case. Also, we mention the importance of proceeding to cytogenetic study, which in our case helped us to confirm the diagnosis made by flow cytometry by highlighting a cytogenetic abnormality that is specific to B acute lymphoblastic leukemia.

Indexed as

Chromosomes, Human, Pair 21Precursor Cell Lymphoblastic Leukemia-LymphomaCD79 AntigensChildFlow CytometryHumansImmunophenotypingIn Situ Hybridization, FluorescenceMaleCD79 AntigensCD79A protein, humanB-cell acute lymphoblastic leukemiaCD79aFlow cytometric immunophenotyping (FCI)iAMP21

Identifiers

PMID34706776
PMCPMC8555128
OpenAlexW3210749533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.